poisar

Stocks · News reference

Sionna Therapeutics Q2 EPS $(0.66) Misses $(0.65) Estimate

Aug 6, 2026, 11:39 AMBenzinga Newsdesk

Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 60.98 percent decrease over losses of $(0.41) per share

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SION
Source
benzinga
Observed
Aug 6, 2026, 11:39 AM
Checked
Aug 6, 2026, 11:39 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 26, 2026, 8:30 PMGlancy Prongay Wolke & Rotter Llp

    Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

    Glancy Prongay Wolke & Rotter LLP is investigating Sionna Therapeutics for potential securities law violations following the company's announcement of a primary endpoint miss in its PreciSION CF Phase 2a trial on August 10, 2026. The news triggered a 91.2% stock price decline, falling from approximately $46.64 to $4.10 per share, prompting a class action lawsuit on behalf of affected shareholders.

    Read original at globenewswire-inc
    SION
  2. Aug 25, 2026, 6:50 PMThe Law Offices Of Frank R. Cruz

    Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

    The Law Offices of Frank R. Cruz is investigating Sionna Therapeutics for potential federal securities law violations following the company's announcement of a primary endpoint miss in its PreciSION CF Phase 2a trial on August 10, 2026. The news triggered a 91.2% stock price decline, falling from approximately $46.64 to $4.10 per share, causing significant investor losses.

    Read original at globenewswire-inc
    SION
  3. Aug 20, 2026, 7:30 PMProsper Junior Bakiny

    Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead

    Vertex Pharmaceuticals strengthens its dominant position in the cystic fibrosis market after competitor Sionna Therapeutics failed a clinical trial for its CF drug candidate. With continued CF portfolio improvements, patent exclusivity until the late 2030s, and promising newer medicines like Casgevy for rare blood diseases and Journavx for pain management, Wall Street remains bullish on Vertex's growth prospects.

    Read original at the-motley-fool
    VRTXSIONABBVCRSP